

Tirzepatide 40 mg

TZ-2026-008 Lot NOT PROVIDED Analyzed October 21, 2026



TIMELINE

ORDERED
October 17, 2026
RECEIVED
October 19, 2026
ANALYZED
October 21, 2026

SAMPLE

NAME
Tirzepatide 40 mg
EXPECTED
Tirzepatide
AMOUNT
1 vial, lyophilized powder

TESTING

CLIENT
PDB
TEST TYPE
Content & purity
METHOD
HPLC-UV

CONTENT, HOW MUCH IS IN IT

Not detected

Label claim: 40 mg


IDENTITY, WHAT IT IS

Not detected

No tirzepatide detected in either of two injections

CHROMATOGRAM

HPLC-UV



● 3.73 min, Unidentified component

ANALYST COMMENTS

White lyophilized powder, blue-cap vial, received sealed. The sample was injected twice and tirzepatide was not found in either injection (detection limit about 0.2 mg per vial). No peptide was detected at any point in the run. The only significant peak is an early eluting unidentified UV-absorbing component.

ANALYST SIGNATURE

Max Barrett
Lab Director, PuriLab Analytical
Analysis date: October 21, 2026

VERIFICATION CODE

TZ-BLXC-PVFK
Verify at purilab.org/verify/TZ-BLXC-PVFK

SCAN TO VERIFY



TZ-BLXC-PVFK

Results apply solely to the sample as received and are not representative of any larger lot, batch, or production run. Findings are limited to the analytes stated above. PuriLab Analytical is an independent testing laboratory, is not CLIA certified or ISO 17025 accredited, does not sell or distribute any substance, and makes no representation as to the safety, legality, or fitness of any material for any use.